UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

The New England journal of medicine, 2013-08, Vol.369 (8), p.754-762

2013

Volltextzugriff (PDF)

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Scandinavian journal of gastroenterology, 2011-03, Vol.46 (3), p.310-318

2011

Volltextzugriff (PDF)

Exploring disease-related and treatment-related issues and concerns experienced by adults with spondyloarthritis, inflammatory bowel disease and psoriasis to identify unmet needs: a qualitative clinical concept mapping study

BMJ open, 2023-12, Vol.13 (12), p.e071586-e071586

2023

Volltextzugriff (PDF)

Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study

Scandinavian journal of gastroenterology, 2018-08, Vol.53 (8), p.930-937

2018

Volltextzugriff (PDF)

Identifying and understanding disease burden in patients with inflammatory bowel disease

BMJ open gastroenterology, 2022-10, Vol.9 (1), p.e000994

2022

Volltextzugriff (PDF)

The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment

Scandinavian journal of gastroenterology, 2024-08, Vol.59 (8), p.1-924

2024

Volltextzugriff (PDF)

Biosimilars for Management of Crohn Disease

Annals of internal medicine, 2019-01, Vol.170 (2), p.129

2019

Volltextzugriff (PDF)

Challenges and opportunities for IBD drug development: from early stage to regulatory approval

Gut, 2020-07, Vol.69 (7), p.1157-1161

2020

Volltextzugriff (PDF)

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Gut, 2014-06, Vol.63 (6), p.919-927

2014

Volltextzugriff (PDF)

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

Drugs (New York, N.Y.), 2024-11

2024

Volltextzugriff (PDF)

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD

Inflammatory bowel diseases, 2014-10, Vol.20 (10), p.1714-1721

2014

Volltextzugriff (PDF)

A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence

Scandinavian journal of gastroenterology, 2022-03, Vol.57 (3), p.274-281

2022

Volltextzugriff (PDF)

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-07, Vol.34 (1), p.51-58

2011

Volltextzugriff (PDF)

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Liver international, 2018-03, Vol.38 (3), p.532-541

2018

Volltextzugriff (PDF)

Which biological agents are most appropriate for ulcerative colitis?

Annals of internal medicine, 2014-05, Vol.160 (10), p.733

2014

Volltextzugriff (PDF)

Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.22-33.e6

2024

Volltextzugriff (PDF)

Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics

Scandinavian journal of gastroenterology, 2022-09, Vol.57 (9), p.1051-1057

2022

Volltextzugriff (PDF)

Methotrexate for inflammatory bowel disease: time for reconsideration

Expert review of gastroenterology & hepatology, 2019-05, Vol.13 (5), p.407-409

2019

Volltextzugriff (PDF)

Telephone reminders reduced the non-attendance rate in a gastroenterology outpatient clinic

Danish medical journal, 2015-06, Vol.62 (6)

2015

Volltextzugriff (PDF)

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

Scandinavian journal of gastroenterology, 2012-05, Vol.47 (5), p.518-527

2012

Volltextzugriff (PDF)

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

Journal of Crohn's and colitis, 2012-02, Vol.6 (1), p.108-111

2012

Volltextzugriff (PDF)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

BMJ open, 2014-12, Vol.4 (12), p.e005887-e005887

2014

Volltextzugriff (PDF)

Tegaserod in treatment of women with irritable bowel syndrome

Ugeskrift for læger, 2007-06, Vol.169 (23), p.2190

2007

Volltextzugriff (PDF)

Microbial organic nitrogen transformations in the river swale-ouse system

Ainsworth, Andrew Mark

1998

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(112)
Dissertationen
(1)

Sprache

Englisch
(110)
Spanisch
(2)
Dänisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Exploring disease-related and treatment-related issues and concerns experienced by adults with spondyloarthritis, inflammatory bowel disease and psoriasis to identify unmet needs: a qualitative clinical concept mapping study

Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study

Identifying and understanding disease burden in patients with inflammatory bowel disease

The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment

Biosimilars for Management of Crohn Disease

Challenges and opportunities for IBD drug development: from early stage to regulatory approval

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD

A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Which biological agents are most appropriate for ulcerative colitis?

Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis

Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics

Methotrexate for inflammatory bowel disease: time for reconsideration

Telephone reminders reduced the non-attendance rate in a gastroenterology outpatient clinic

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

Tegaserod in treatment of women with irritable bowel syndrome

Microbial organic nitrogen transformations in the river swale-ouse system

Suchergebnisse filtern